Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,251 - 1,300 out of 6,641

Document Document Title
WO/2001/087911A1
A method is disclosed for identifying compound defined by pharmacophores which compound affect protein-protein interactions. The method involves determining functional residues of at least one protein of a protein-protein interaction of ...  
WO/2001/087309A1
Coumermycin analogs of general formula I: wherein X, a linking group, is selected from the group consisting of alkyl, aryl, diaryl, substituted alkyl, substituted aryl, alkyl with hereroatoms in the chain, heteroaryl, cyclic and bicyclic...  
WO/2001/087912A1
The invention relates to a polymorphic form of azithromycin dihydrate (9-desoxo-9a-aza-9a-methyl-9a-homoerythromycin A) showing endothermy in differential scanning calorimetry (DSC) at 139° C, when recorded in an open aluminum crucible ...  
WO/2001/087807A2
The present invention relates to a cost effective and industrially advantageous process for the selective methylation of a hydroxy group at the 6 position of erythromycin A derivatives.  
WO2000064484A3
Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the...  
WO/2001/083448A2
Chemotherapy of malignant tumors is seriously restricted by the fact that available cytostatics are often not capable of differentiating between normal and malignant tissue. The aim of the invention is therefore to improve the selectivit...  
WO/2001/081358A1
Methods for treating or preventing bacterial or protozoal infections in mammals by administering a single dose of an antibiotic composition comprising a mixture of azalide isomers and a pharmaceutically acceptable vehicle are disclosed. ...  
WO/2001/079244A1
Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds according to FORMULA (V), wherein, Ring 1 comprises a cyclic or heterocyclic ring, or aryl or heteroaryl ring, all of said rings comprising 4 to 8 carbon atoms, a...  
WO/2001/079245A1
The invention relates to flavone and isoflavone glycoside derivatives of general formula (I): [A¿1?-C(=O)O]¿m?-[X-O-Z]-[O-C(=O)-A¿2?]¿n? (I), wherein [X-O-Z] represents a flavone or isoflavone glycoside structure, wherein X represent...  
WO/2001/079520A1
The present invention relates to hybrid glycosylated products, and in particular, to natural products such as polyketides and glycopeptides, and to processes for their preparation. The invention is particularly concerned with recombinant...  
WO2001021608A3
Described are novel flavonoids of formula (I) wherein: A and E form together a C-C or C=C bond, R1, R2, R3, and R4 are chosen from: H, OH, and from the substituents, O(CH2)n-aromatic group, n=0-8, O(CH2)n N(CH3)q with n=0-8, q=0-3, O(CH2...  
WO/2001/077134A2
Disclosed herein is a process for the preparation of erythromycin derivatives, or pharmaceutically acceptable salts thereof, which contain an optionally substituted propargyl group at the 6-O-position.  
WO/2001/077135A1
The present invention relates to a process for preparing 6-methyl erythromycin A. The present invention, for the methylation reaction, forms nitrogen oxide only at 3'-dimethylamino group by a suitable oxidizing agent thereby resulting in...  
WO/2001/076602A1
Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual dysfunction or for enhancing apormorphine effectiv...  
WO2000056746A3
A synthesis of [2.2.1]bicyclo nucleosides which is shorter and provides higher overall yields proceeds via the key intermediate of general formula (III), wherein R4 and R5 are, for instance, sulfonates and R7 is, for instance, a halogen ...  
WO/2001/072763A1
The invention concerns a method for preparing 9-deoxo-8a-aza-(8a-alkyl)-8a-homoerythromycin A and its 8a-alkyl derivatives from 9-deoxo-9(Z)-hydroxyiminoerythromycin A via a Beckmann stereospecific rearrangement in a reaction medium usin...  
WO/2001/070758A1
A process for producing purified erythromycin from which erythromycin F has been removed. The process comprises using a combination of (i) an organic solvent and (ii) water or an aqueous solution of an inorganic substance and/or an organ...  
WO/2001/068662A1
High purity clarithromycin of Form II crystals can be easily prepared in a high yield by a process comprising the steps of: protecting the 9-oxime hydroxy group of erythromycin A 9-oxime or a salt thereof with a tropyl group and the 2'- ...  
WO/2001/068867A1
The complete sequence of the gene cluster for the monensin type I polyketide synthase, from S. cinnamonensis, is provided. Thus variant polyketides containing monensin-derived elements can be genetically engineered. Furthermore there are...  
WO/2001/064224A1
The present invention relates to processes for preparing protected silylated clarithromycin oxime, preferably 6-O-methy-2',4'-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime('S-MOP oxime'), and for converting protected s...  
WO/2001/064701A1
A simple and easy process for preparing pharmacologically useful flavonoids exhibiting effects of inhibiting aldose reductase, extinguishing active oxygen, inhibiting carcinogenesis promotion, counteracting inflammation, and so on. Speci...  
WO2000042055A3
3'-Des-dimethylamino-9-oxyimino macrolides of formula (I) endowed with anti-inflammatory activity and their pharmaceutical use are described.  
WO/2001/064700A1
A compound JK represented by the following general formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R is hydrogen or -CH¿3?). The compound has an excellent antibacterial effect on drug-resistant bacteria such...  
WO/2001/063539A2
The invention relates to novel methods for using macrolide anti-infective agents. The macrolide anti-infective agents demonstrate antibacterial activity against multi-drug resistant strains of bacteria and, in particular, methicillin-res...  
WO/2001/060833A2
The present invention provides novel macrolide compounds of the formulas (I, II, III or IV) wherein: R is hydroxyl or methoxy; R?1¿ is selected from the group consisting of hydrogen, hydroxyl, halide, NH¿2?, OR?9¿, (a, b, c, and d) wh...  
WO/2001/060390A1
New toralactone of general formula [A] extracted from seed of cassiae obtusifollia L. and its derivative, wherein R?3¿ is H or acyl of C¿2?-C¿4?, R?1¿, R?2¿ is identity or difference, independently H, saccharide group, acyl of C¿2?...  
WO/2001/060832A2
The invention relates to a compound of formula (I) wherein R¿1? is a sugar; R¿2? is -CH¿2?-O-(R¿7?)m, R¿7? representing a sugar, or R¿2? is -COOH; R¿3? is an epoxide-comprising group, C¿1?-C¿6?-alkyl or C¿2?-C¿6?-alkenyl, unsu...  
WO/2001/059126A2
The invention provides a nucleic acid molecule comprising: a nucleotide sequence as shown in SEQ ID No. 35; wherein said sequence preferably encodes or is complementary to a sequence encoding a nystatin PKS enzyme or a part thereof. Also...  
WO2000057866A3
The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A ...  
WO/2001/054691A1
Nitrate salts of antimicrobial agents for the preparation of antimicrobial medicaments, specifically antiviral, antifungal and antibacterial medicaments.  
WO/2001/055158A1
Antibiotic compositions comprising an equilibrium mixture of azalide isomers, water, and one or more acids, and methods for preparing such compositions, are disclosed. The antibiotic compositions can be advantageously stabilized by addin...  
WO1999064040A8
Novel multibinding compounds are disclosed. The compounds of the invention comprise 2-10 polyene macrolide antibiotic ligands covalently connected, each of said ligands being capable of binding to a ligand binding site in a cellular or v...  
WO/2001/051059A1
The present invention relates to processes for converting clarithromycin Form I to clarithromycin Form II, which include slurrying clarithromycin the Form I in water. The present invention also relates to processes for the preparation of...  
WO/2001/051061A1
The present invention provides a new class of polyene macrolide derivatives useful for treating or preventing fungal infections. The new polyene macrolide derivatives exhibit surprisingly superior antifungal activity and water solubility...  
WO/2001/049699A1
Compounds of the formula (1), (1'), (2), (2'), (3), (3') (101), (102), or (103) wherein R¿a? is substituted or unsubstituted alkyl (1-10C); substituted or unsubstituted alkenyl (2-10C); substituted or unsubstituted alkynyl (2-10C); subs...  
WO2000063361A3
A multiple-plasmid system for heterologous expression of polyketides facilitates combinatorial biosynthesis. The method can be extended to any modular polyketide synthase (PKS) or non-ribosomal peptide synthase (NRPS) and has the potenti...  
WO/2001/049697A1
This invention relates to a method for preparing azithromycin dihydrate from crude azithromycin by the gradual crystallization of azithromycin from acetone by the addition of a minimal amount of water to effect crystal formation is discl...  
WO/2001/047507A2
This invention relates to combinations of an abl-, PDGF-Receptor-and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to $g(a)¿1?-acidic glycoprotein (AGP), as well as to pharmaceutical preparations ...  
WO/2001/046211A1
The invention concerns a method for preparing 9-deoxo-9(Z)-hydroxyiminoerythromycin A of formula (I) wherein: starting with 9-deoxo-9(E)-hydroxyiminoerythromycin A by reaction with a base in water or a dialkylketone type water/solvent mi...  
WO1999063937A9
Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptogramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more prot...  
WO2001014393A3
The invention relates to spherical telithromycin clusters and to a method for the production thereof characterized in that a telithromycin crystal suspension is prepared, said crystals are coated with a telithromycin insoluble phase whic...  
WO/2001/044262A1
The present invention relates to processes for converting clarithromycin Form 0 to clarithromycin Form II, which include slurrying clarithromycin the Form 0 in water. The present invention also relates to processes for the preparation of...  
WO/2001/044186A1
Compounds of general formula (1), prodrugs of the same, or pharmaceutically acceptable salts of both are useful as preventive or therapeutic drugs for disease due to increased sodium/proton exchange: (1) wherein R is an optionally substi...  
WO2000068413A8
Fermentattion of Nocardia sp- ATCC-202099 in the presence of a halogen- or hydroxy-substituted tryptophan precursor yields a novel corresponding halogen- or hydroxy-substituted nocathiacin compound which has broad spectrum antibiotic act...  
WO/2001/041775A2
Methylated procyanidins which include procyanidin monomers and their oligomers are useful in the modulation of inflammatory pathways, in the maintenance of the vascular health of a mammal and as an antibacterial treatment. They can be in...  
WO/2001/040242A2
The present invention relates to a novel 6-O-methylerythromycin A crystal form, a process for preparing the crystal form, and methods for using the crystal form to prepare a 6-O-methylerythromycin A crystal form II.  
WO/2001/040241A2
The present invention relates to 6-O-alkyl-2-nor-2-substituted ketolide compound or a derivative thereof, a composition comprising the compound and a suitable carrier, a method of preparing the compound, and a method of treatment and pre...  
WO1999063940A3
Disclosed are multibinding compounds which inhibit H<+>/K<+>-ATPase, an enzyme which is involved in the control of acid secretion in the stomach. The multibinding compounds of this invention containing from 2 to 10 ligands covalently att...  
WO/2001/038339A1
Antimitotic terpenoid compounds including sarcodictyin A and diterpenes such as eleutherobin may be obtained from organisms of the order Gorgonacea. Methods of obtaining or preparing such compounds are provided, as are novel antimitotic ...  
WO/2001/038340A1
Clarithromycin can be easily prepared by reacting erythromycin A N-oxide with a methylating agent to obtain 6-O-methylerythromycin A N-oxide; and treating 6-O-methylerythromycin A N-oxide obtained above with a reducing agent in a high yi...  

Matches 1,251 - 1,300 out of 6,641